SAN DIEGO, Jan. 19, 2018 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, today announced participation in three upcoming healthcare events. ViaCyte is developing novel stem cell-derived islet replacement therapies for insulin-requiring diabetes. The company's lead PEC-DirectTM product candidate is in clinical development as a potential functional cure for patients with type 1 diabetes with the highest risk of life threatening acute complications. The related PEC-EncapTM product candidate, and a candidate called PEC-QT based on the use of a gene edited immune-evasive cell line, are also in development and have the potential to provide a functional cure for essentially all patients with insulin-requiring diabetes, both type 1 and type 2.
Details of the events are as follows:
|
Event: |
Phacilitate Cell & Gene Therapy World |
|
Speaker: |
Dr. Mark Zimmerman, Vice President, Strategy and Business Development |
|
Title: |
Case study: Developing a cell therapy combination product for diabetes |
|
Date/Time: |
January 24, 4:05 PM ET |
|
Location: |
Hyatt Regency, Miami, Florida |
|
Event: |
Arab Health Exhibition and Congress |
|
Presenters: |
Dr. Paul Laikind, President and CEO |
|
Date/Time: |
January 29 to February 1 |
|
Location: |
Johnson & Johnson Exhibit in the UAE Ministry of Health area; Dubai International Convention and Exhibition Centre, Dubai, United Arab Emirates |
|
Event: |
2018 Rachmiel Levine-Arthur Riggs Diabetes Research Symposium |
|
Speaker: |
Dr. Evert Kroon, Senior Director, Research Physiology |
|
Session: |
Encapsulation and Mechanical Immunoprotective Approaches in Beta Cell Replacement |
|
Title: |
Macroencapsulation Approaches |
|
Date/Time: |
February 1, 8:45 AM PT |
|
Location: |
The Langham Huntington, Pasadena, California |
For more information about ViaCyte's participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/
About ViaCyte
ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on the derivation of pancreatic progenitor cells from stem cells, which are then implanted in durable and retrievable cell delivery devices. Once implanted and matured, these cells are designed to secrete insulin and other pancreatic hormones in response to blood glucose levels. ViaCyte has two product candidates in clinical-stage development. The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap™ (also known as VC-01) product candidate delivers the same pancreatic progenitor cells in an immunoprotective device and is being developed for all patients with diabetes, type 1 and type 2, who use insulin. ViaCyte is also developing immune-evasive 'universal donor' stem cell lines, from its proprietary CyT49 cell line, expected to further broaden the availability of cell therapy for diabetes and other indications. ViaCyte is headquartered in San Diego, California. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit www.viacyte.com and connect with ViaCyte on Twitter and Facebook.
SOURCE ViaCyte, Inc.